IDH1 and IDH2 Mutations in Gliomas

Cited by (1,012)

Items 901–1,000 of 1,012

1. Selective acquisition of IDH1 R132C mutations in astrocytomas associated with Li-Fraumeni syndrome
   Takuya Watanabe, Anne Vital, Sumihito Nobusawa, Paul Kleihues, Hiroko Ohgaki · 2009 · Acta Neuropathologica
2. Mutations in Epigenetic Modifiers in Myeloid Malignancies and the Prospect of Novel Epigenetic-Targeted Therapy
   Amir T. Fathi, Omar Ibrahim Abdel-Wahab · 2011 · Advances in Hematology
3. Mutations in MDH2, Encoding a Krebs Cycle Enzyme, Cause Early-Onset Severe Encephalopathy
   Samira Ait-El-Mkadem, Manal Abdel Dayem, Mirjana Gušić, Annabelle Chaussenot, Sylvie Bannwarth, Bérengère François, Emmanuelle C. Genin, Konstantina Fragaki, Catharina M.L. Volker‐Touw, Christelle Vasnier et al. · 2016 · The American Journal of Human Genetics
4. Glioblastoma Therapy in the Age of Molecular Medicine
   Luiz Henrique Geraldo, Celina Garcia, Anna Carolina Carvalho da Fonseca, Luiz Gustavo Dubois, Tânia Cristina Leite de Sampaio e Spohr, Diana Matias, Eduardo Sabino de Camargo Magalhães, Rackele Ferreira do Amaral, Bárbara Gomes da Rosa, Izabella Grimaldi et al. · 2018 · Trends in cancer
5. Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM)
   Hannah K. Carter, Josue A. Samayoa, Ralph H. Hruban, Rachel Karchin · 2010 · Cancer Biology & Therapy
6. Children are not just little adults: recent advances in understanding of diffuse intrinsic pontine glioma biology
   Kristin Schroeder, Christine M. Hoeman, Oren Josh Becher · 2013 · Pediatric Research
7. MicroRNA-183 upregulates HIF-1α by targeting isocitrate dehydrogenase 2 (IDH2) in glioma cells
   Hirotomo Tanaka, Takashi Sasayama, Kazuhiro Tanaka, Satoshi Nakamizo, Masamitsu Nishihara, Katsu Mizukawa, Masaaki Kohta, Junji Koyama, Shigeru Miyake, Masaaki Taniguchi et al. · 2012 · Journal of Neuro-Oncology
8. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting
   Anna Tietze, Changho Choi, Bruce Mickey, Elizabeth Anne Maher, Benedicte Parm Ulhøi, Ryan Sangill, Yasmin Lassen–Ramshad, Slávka Lukacova, Leif Østergaard, Gorm von Öettingen · 2017 · Journal of neurosurgery
9. The management of low-grade gliomas in adults
   Ramin A. Morshed, Jacob S. Young, Shawn L. Hervey‐Jumper, Mitchel Stuart Berger · 2019 · Journal of Neurosurgical Sciences
10. A machine learning framework to trace tumor tissue-of-origin of 13 types of cancer based on DNA somatic mutation
    Bingsheng He, Chan Dai, Jidong Lang, Pingping Bing, Geng Tian, Bo Wang, Jialiang Yang · 2020 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
11. Updates in IDH-Wildtype Glioblastoma
    Jawad M. Melhem, Jay S. Detsky, Mary Jane Lim-Fat, James Perry · 2022 · Neurotherapeutics
12. Predictors of preoperative and early postoperative seizures in patients with intra‐axial primary and metastatic brain tumors: A retrospective observational single center study
    Marco Skardelly, Elina Brendle, Susan Noell, Felix Behling, Thomas V. Wuttke, Jens Schittenhelm, Sotirios Bisdas, Christoph Meisner, Sabine Rona, Marcos Soares Tatagiba et al. · 2015 · Annals of Neurology
13. Brain stem cells as the cell of origin in glioma
    Aram Sandaldjian Modrek · 2014 · World Journal of Stem Cells
14. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas
    FABIO MASSAITI IWAMOTO, Andreas Felix Hottinger, Sasan Karimi, Elyn Riedel, Jocelynn Dantis, Maryam Jahdi, K. Panageas, Andrew B. Lassman, Lauren E. Abrey, Martin Fleisher et al. · 2011 · Neuro-Oncology
15. Understanding inherited genetic risk of adult glioma – a review
    Terri Rice, Daniel Honore Lachance, Annette M. Molinaro, Jeanette E. Eckel‐Passow, Kyle M. Walsh, Jill S. Barnholtz‐Sloan, Quinn T. Ostrom, Stephen Starko Francis, Joseph Leo Wiemels, Robert Brian Jenkins et al. · 2015 · Neuro-Oncology Practice
16. Moving toward molecular classification of diffuse gliomas in adults
    Brett James Theeler, W. K. Alfred Yung, Gregory N. Fuller, John de Groot · 2012 · Neurology
17. Cancer-associated Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation and d-2-Hydroxyglutarate Stimulate Glutamine Metabolism under Hypoxia
    Zachary J. Reitman, Christopher G. Duncan, Ethan C. Poteet, Ali Winters, Liang‐Jun Yan, David M. Gooden, Ivan Spasojević, László G. Boros, Shao-Hua Yang, Hai Yan · 2014 · Journal of Biological Chemistry
18. Epigenetics in Cancer: A Hematological Perspective
    Maximilian F. Stahl, Nathan Kohrman, Steven D. Gore, Tae Kon Kim, Amer Methqal Zeidan, Thomas Prébet · 2016 · PLoS Genetics
19. Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer
    Sandeep Balu Shelar, Eun‐Hee Shim, Garrett J. Brinkley, Anirban Kundu, Francesca Carobbio, Tyler L. Poston, Jubilee C. Tan, Vishwas Parekh, Daniel G. Benson, David K. Crossman et al. · 2018 · Clinical Cancer Research
20. Integrated molecular characterization of IDH ‐mutant glioblastomas
    Andrey Korshunov, Belén Casalini, Lukas Chávez, Thomas Hielscher, Martin Sill, Marina Vladimirovna Ryzhova, Tanvi S. Sharma, Daniel Schrimpf, Damian Stichel, David Capper et al. · 2018 · Neuropathology and Applied Neurobiology
21. Targeting IDH1-Mutated Malignancies with NRF2 Blockade
    Yang Liu, Yanxin Lu, Orieta Celiku, Aiguo Li, Qixin Wu, Yiqiang Zhou, Chunzhang Yang · 2018 · JNCI Journal of the National Cancer Institute
22. The IDH-TAU-EGFR triad defines the neovascular landscape of diffuse gliomas
    Ricardo Gargini, Berta Segura‐Collar, Beatriz Herránz, Vega García‐Escudero, Andrés Romero-Bravo, Felipe Javier Núñez, Daniel García‐Pérez, Jacqueline Gutiérrez-Guamán, Ángel Ayuso‐Sacido, Joan Seoane et al. · 2020 · Science Translational Medicine
23. Quantitative proteomics reveals specific metabolic features of acute myeloid leukemia stem cells
    Simon Raffel, Daniel Klimmeck, Mattia Falcone, Aykut Demir, Alireza Pouya, Petra Zeisberger, Christoph Lutz, Marco Tinelli, Oliver E. Bischel, Lars Bullinger et al. · 2020 · Blood
24. Glutamatergic Mechanisms in Glioblastoma and Tumor-Associated Epilepsy
    Falko Lange, Max Frederik Hörnschemeyer, Timo Kirschstein · 2021 · Cells
25. Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas
    Gi-Ming Wang, Gino Cioffi, Nirav T. Patil, Kristin A. Waite, Robert Lanese, Quinn T. Ostrom, Carol A. Kruchko, Michael E. Berens, James R. Connor, Justin Durla Lathia et al. · 2021 · Neuro-Oncology
26. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma
    Gabriel Alzial, Ophélie Renoult, François Paris, Catherine Gratas, Anne Clavreul, Claire Pecqueur · 2021 · Oncogene
27. TET2 Mutations Affect Non-CpG Island DNA Methylation at Enhancers and Transcription Factor–Binding Sites in Chronic Myelomonocytic Leukemia
    Jumpei Yamazaki, Jaroslav Jelı́nek, Yue Lu, Matteo Cesaroni, Jozef Madžo, Frank Neumann, Rong Lucy He, Rodolphe F. Taby, Aparna Vasanthakumar, Trisha A. Macrae et al. · 2015 · Cancer Research
28. Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients
    Akitake Mukasa, Shunsaku Takayanagi, Kuniaki Saito, Junji Shibahara, Yusuke Tabei, Kazuhide Furuya, Takafumi Ide, Yoshitaka Narita, Ryo Nishikawa, Keisuke Ueki et al. · 2011 · Cancer Science
29. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma
    Stefan Pusch, Leonille Schweizer, Ann-Christin Beck, Johanna-Marie Lehmler, Susanne Weißert, Jörg Balß, Aubry K. Miller, Andreas von Deimling · 2014 · Acta Neuropathologica Communications
30. The Evolving Molecular Genetics of Low-grade Glioma
    Sriram Venneti, Jason T. Huse · 2015 · Advances in Anatomic Pathology
31. Metabolic dependencies and vulnerabilities in leukemia
    Marissa Rashkovan, Adolfo A. Ferrando · 2019 · Genes & Development
32. Chromatin Remodeling Defects in Pediatric and Young Adult Glioblastoma: A Tale of a Variant <scp>H</scp>istone 3 Tail
    Fontebasso, Adam M., Liu, Xiao‐Yang, Sturm, Dominik, Jabado, Nada · 2013 · Brain Pathology
33. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial
    Benedikt Wiestler, David Capper, Volker Hovestadt, Martin Sill, David Jones, Christian Johannes Hartmann, Joerg Felsberg, Michael Platten, W. Feiden, Kathy Keyvani et al. · 2014 · Neuro-Oncology
34. Quantitative Analysis of Energy Metabolic Pathways in MCF-7 Breast Cancer Cells by Selected Reaction Monitoring Assay
    Andrei P. Drabovich, Maria P. Pavlou, Apostolos Dimitromanolakis, Eleftherios P. Diamandis · 2012 · Molecular & Cellular Proteomics
35. Molecular and Morphologic Correlates of the Alternative Lengthening of Telomeres Phenotype in High‐Grade Astrocytomas
    Doreen N. Nguyen, Christopher M. Heaphy, Roeland F. de Wilde, Brent A. Orr, Yazmín Odia, Charles G. Eberhart, Alan Keith Meeker, Fausto J. Rodríguez · 2012 · Brain Pathology
36. Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status
    Rachel L. Delfanti, David Eric Piccioni, Jason Handwerker, Naeim Bahrami, Anithapriya Krishnan, Roshan A. Karunamuni, Jona Ashok Hattangadi-Gluth, Tyler M. Seibert, Ashwin Srikant, Karra A. Jones et al. · 2017 · Journal of Neuro-Oncology
37. Succinate Dehydrogenase–Deficient Gastrointestinal Stromal Tumors
    Ahmad Ibrahim, Shefali Chopra · 2019 · Archives of Pathology & Laboratory Medicine
38. Isocitrate dehydrogenase mutations in gliomas
    Changcun Guo, Christopher J. Pirozzi, Giselle Yvette Lopez, Hai Yan · 2011 · Current Opinion in Neurology
39. Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses
    Joanna Obacz, Silvia Pastoreková, Borek Vojtesek, Roman Hrstka · 2013 · Molecular Cancer
40. D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice
    Esra A. Akbay, Javid J. Moslehi, Camilla Laulund Christensen, Supriya K. Saha, Jeremy H. Tchaicha, Shakti H Ramkissoon, Kelly M. Stewart, Julián Carretero, Eiki Kikuchi, Haikuo Zhang et al. · 2014 · Genes & Development
41. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression‐free survival and prolonged postrecurrence survival
    Niklas Thon, Sabina Eigenbrod, Simone Kreth, Juergen Lutz, Joerg‐Christian Tonn, Hans A. Kretzschmar, Aurelia Peraud, Friedrich-Wilhelm Kreth · 2011 · Cancer
42. Pancreatic tumor cell metabolism: Focus on glycolysis and its connected metabolic pathways
    Fabienne Guillaumond, Juan Iovanna, Sophie Vasseur · 2014 · Archives of Biochemistry and Biophysics
43. Direct mutation analysis by high-throughput sequencing: From germline to low-abundant, somatic variants
    Michael C. Gundry, Jan Vijg · 2011 · Mutation research. Fundamental and molecular mechanisms of mutagenesis
44. Hyperpolarized [1-13C] Glutamate: A Metabolic Imaging Biomarker of IDH1 Mutational Status in Glioma
    Myriam M. Chaumeil, Peder E. Z. Larson, Sarah M. Woods, Larry Cai, Pia Eriksson, Aaron E. Robinson, Janine Lupo, Daniel B. Vigneron, Sarah J. Nelson, Russell O. Pieper et al. · 2014 · Cancer Research
45. Rare insights into cancer biology
    Julie Adam, Mingming Yang, Tomoyoshi Soga, Patrick J. Pollard · 2013 · Oncogene
46. A holistic view of cancer bioenergetics: mitochondrial function and respiration play fundamental roles in the development and progression of diverse tumors
    Md Maksudul Alam, Sneha Lal, Keely E. FitzGerald, Zhang Li · 2016 · Clinical and Translational Medicine
47. Proteome of Metastatic Canine Mammary Carcinomas: Similarities to and Differences from Human Breast Cancer
    Robert Klopfleisch, Patricia Klose, Christoph Weise, Angelika Bondzio, Gerd Multhaup, Ralf Einspanier, Achim Dieter Gruber · 2010 · Journal of Proteome Research
48. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy
    Francesca Branzoli, Anna Luisa Di Stefano, Laurent Capelle, Chris Ottolenghi, Romain Valabrègue, Dinesh Kumar Deelchand, Franck Bielle, Chiara Villa, Bertrand Baussart, Stéphane Lehéricy et al. · 2017 · Neuro-Oncology
49. D-2-Hydroxyglutarate Is an Intercellular Mediator in IDH-Mutant Gliomas Inhibiting Complement and T Cells
    Lingjun Zhang, Mia Dahl Sørensen, Bjarne Winther Kristensen, Guido Reifenberger, Thomas M. McIntyre, Feng Lin · 2018 · Clinical Cancer Research
50. Extent of Surgical Resection in Lower-Grade Gliomas: Differential Impact Based on Molecular Subtype
    Sohil Harshad Patel, Anmol Gupta Bansal, E.B. Young, Prem Pradeep Batchala, James T. Patrie, M. Beatriz S. Lopes, Rajan Jain, Camilo E. Fadul, David Schiff · 2019 · American Journal of Neuroradiology
51. Angioimmunoblastic T‐cell lymphoma contains multiple clonal T‐cell populations derived from a common TET2 mutant progenitor cell
    Wenqing Yao, Fangtian Wu, Wenyan Zhang, Shih‐Sung Chuang, Joe Sneath Thompson, Zi Chen, Shaowei Zhang, Alexandra Clipson, Ming Wang, Hongxiang Liu et al. · 2019 · The Journal of Pathology
52. Metformin as Potential Therapy for High-Grade Glioma
    Marek Mazurek, Jakub Litak, Piotr Kamieniak, Bartłomiej Kulesza, Katarzyna E. Jonak, Jacek Baj, Cezary Grochowski · 2020 · Cancers
53. Rapid Intraoperative Molecular Characterization of Glioma
    Ganesh M. Shankar, Joshua M. Francis, Mikael L. Rinne, Shakti H Ramkissoon, Franklin W. Huang, Andrew Sean Venteicher, Elliot H. Akama‐Garren, Yun Jee Kang, Nina Lelic, James C. Kim et al. · 2015 · JAMA Oncology
54. Frequent IDH1/2 mutations in intracranial chondrosarcoma: a possible diagnostic clue for its differentiation from chordoma
    Motohiro Arai, Sumihito Nobusawa, Hayato Ikota, Sunao Takemura, Yoichi Nakazato · 2012 · Brain Tumor Pathology
55. Pyruvate Kinase M2 Expression, but Not Pyruvate Kinase Activity, Is Up-Regulated in a Grade-Specific Manner in Human Glioma
    Joydeep Mukherjee, Joanna J. Phillips, Shichun Zheng, John K. Wiencke, Sabrina M. Ronen, Russell O. Pieper · 2013 · PLoS ONE
56. Neoplastic cells are a rare component in human glioblastoma microvasculature
    Fausto J. Rodríguez, Brent A. Orr, Keith Lloyd Ligon, Charles G. Eberhart · 2012 · Oncotarget
57. Transcriptional diversity of long-term glioblastoma survivors
    Naamit Kurshan Gerber, Anuj Goenka, Şevin Turcan, Marsha Reyngold, Vladimir Makarov, Kasthuri S. Kannan, Kathryn P. Beal, Antonio M. P. Omuro, Yoshiya Josh Yamada, Philip H. Gutin et al. · 2014 · Neuro-Oncology
58. The Roles of DNA Methylation in the Stages of Cancer
    Kevin Wyatt McMahon, Enusha Karunasena, Nita Ahuja · 2017 · The Cancer Journal
59. Oncogenic IDH1 Mutations Promote Enhanced Proline Synthesis through PYCR1 to Support the Maintenance of Mitochondrial Redox Homeostasis
    Kate E.R. Hollinshead, Haydn Munford, Katherine L. Eales, Chiara Bardella, Chunjie Li, Cristina Escribano-Gonzalez, Alpesh Thakker, Yannic Nonnenmacher, Katarína Kľučková, Mark Jeeves et al. · 2018 · Cell Reports
60. Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
    Ruichao Chai, Guanzhang Li, Yuqing Liu, Kenan Zhang, Zheng Zhao, Fan Wu, Yuzhou Chang, Bo Pang, Jingjun Li, Yangfang Li et al. · 2021 · Cancer Biology and Medicine
61. Obstacles to Glioblastoma Treatment Two Decades after Temozolomide
    João Victor Roza Cruz, Carolina Batista, Bernardo de Holanda Afonso, Magna Suzana Alexandre‐Moreira, Luiz Gustavo Dubois, Bruno Pontes, Vivaldo Moura‐Neto, Fábio A. Mendes · 2022 · Cancers
62. Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T‐cell‐mediated immunity
    Federica M. Marelli‐Berg, Hongmei Fu, Claudio Mauro · 2012 · Immunology
63. The altered metabolism of tumors: HIF-1 and its role in the Warburg effect
    Marion Stubbs, John R. Griffiths · 2009 · Advances in Enzyme Regulation
64. The role of p53 in glucose metabolism
    Eric C. Cheung, Karen H. Vousden · 2010 · Current Opinion in Cell Biology
65. Genetically-defined metabolic reprogramming in cancer
    Andrew R. Mullen, Ralph J. DeBerardinis · 2012 · Trends in Endocrinology and Metabolism
66. IDH1 R132H Mutation Generates a Distinct Phospholipid Metabolite Profile in Glioma
    Morteza Esmaeili, Bob C. Hamans, Anna Catharina Navis, Remco van Horssen, Tone Frost Bathen, Ingrid Susann Gribbestad, William P. J. Leenders, Arend Heerschap · 2014 · Cancer Research
67. Glioma diagnostics and biomarkers: an ongoing challenge in the field of medicine and science
    Fred H. Hochberg, Nadia A. Atai, David D. Gonda, Michael S Hughes, Brolin Mawejje, Leonora Balaj, Robert S Carter · 2014 · Expert Review of Molecular Diagnostics
68. MRI radiomics analysis of molecular alterations in low-grade gliomas
    Ben Shofty, Moran Artzi, Dafna Ben Bashat, Gilad Liberman, Oz Haim, Alon Kashanian, Felix Bokstein, Deborah T. Blumenthal, Zvi Ram, Tal Shahar · 2017 · International Journal of Computer Assisted Radiology and Surgery
69. The IDH1 Mutation-Induced Oncometabolite, 2-Hydroxyglutarate, May Affect DNA Methylation and Expression of PD-L1 in Gliomas
    Luyan Mu, Yu Long, Changlin Yang, Linchun Jin, Haipeng Tao, Haitao Ge, Yifan Emily Chang, Aida Karachi, Paul Scott Kubilis, Gabriel De Leon et al. · 2018 · Frontiers in Molecular Neuroscience
70. Updates in prognostic markers for gliomas
    Elisa Aquilanti, Julie J. Miller, Sandro Santagata, Daniel P. Cahill, Priscilla Kaliopi Brastianos · 2018 · Neuro-Oncology
71. A fully automated artificial intelligence method for non-invasive, imaging-based identification of genetic alterations in glioblastomas
    Evan Calabrese, Javier E. Villanueva-Meyer, Soonmee Cha · 2020 · Scientific Reports
72. Clinical management and survival outcomes of patients with different molecular subtypes of diffuse gliomas in China (2011–2017): a multicenter retrospective study from CGGA
    Kenan Zhang, Xing Liu, Guanzhang Li, Xin Chang, Shouwei Li, Jing Chen, Zheng Zhao, Jiguang Wang, Tao Jiang, Ruichao Chai · 2022 · Cancer Biology and Medicine
73. Mitochondrial Retrograde Signaling Mediated by UCP2 Inhibits Cancer Cell Proliferation and Tumorigenesis
    Pauline Estèves, Claire Pecqueur, Céline Ransy, Catherine Esnous, Véronique Lenoir, Frédéric Bouillaud, Anne‐Laure Bulteau, Anne Lombès, Carina Prip‐Buus, Daniel Ricquier et al. · 2014 · Cancer Research
74. The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas
    Tareq Adnan Juratli, Matthias Kirsch, Kathrin D. Geiger, Barbara Klink, Elke Leipnitz, Th. Pinzer, Silke Soucek, E. Schrok, G. Schackert, Dietmar Krex · 2012 · Journal of Neuro-Oncology
75. Unsuspected task for an old team: Succinate, fumarate and other Krebs cycle acids in metabolic remodeling
    Paule Bénit, Éric Letouzé, Malgorzata Rak, Laëtitia Aubry, Nelly Burnichon, Judith Favier, Anne‐Paule Gimenez‐Roqueplo, Pierre Rustin · 2014 · Biochimica et Biophysica Acta (BBA) - Bioenergetics
76. Analysis of IDH mutation, 1p/19q deletion, and PTEN loss delineates prognosis in clinical low-grade diffuse gliomas
    N. Sabha, Christiane Brigitte Knobbe-Thomsen, Manjula D. Maganti, S. Al Omar, M. Bernstein, Rob A. Cairns, Besmira Çako, Andreas von Deimling, David Capper, Tak W. Mak et al. · 2014 · Neuro-Oncology
77. Immunohistochemical Analysis of ATRX, IDH1 and p53 in Glioblastoma and Their Correlations with Patient Survival
    Ajay Chaurasia, Sung‐Hye Park, Jeong‐Wook Seo, Chul‐Kee Park · 2016 · Journal of Korean Medical Science
78. Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?
    Ennio Antonio Chiocca, Farshad Nassiri, Justin Qiyun Wang, Pierpaolo Peruzzi, Gelareh Mohammed Zadeh · 2018 · Neuro-Oncology
79. Friend or foe—IDH1 mutations in glioma 10 years on
    L Eric Huang · 2019 · Carcinogenesis
80. Long-term survival with IDH wildtype glioblastoma: first results from the ETERNITY Brain Tumor Funders’ Collaborative Consortium (EORTC 1419)
    Caroline Hertler, Jörg Felsberg, Dorothee Gramatzki, Émilie Le Rhun, Jennifer Leigh Clarke, Riccardo Soffietti, Wolfgang Wick, Olivier Louis Chinot, François Ducray, Patrick Roth et al. · 2023 · European Journal of Cancer
81. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups
    Frédérik Damm, Felicitas R. Thol, Iris H.I.M. Hollink, M Zimmermann, Katarina Reinhardt, Marry M. van den Heuvel‐Eibrink, Christian Michel Zwaan, Válerie de Haas, Ursula Creutzig, Jan‐Henning Klusmann et al. · 2011 · Leukemia
82. Mitochondrial dysfunction in cancer chemoresistance
    Nicoletta Guaragnella, Sergio Giannattasio, Loredana Moro · 2014 · Biochemical Pharmacology
83. Exploiting extension bias in polymerase chain reaction to improve primer specificity in ensembles of nearly identical DNA templates
    Erik S. Wright, Lutfu Safak Yilmaz, Sri Ram, Jeremy M. Gasser, Gregory W. Harrington, Daniel R. Noguera · 2013 · Environmental Microbiology
84. Oncometabolites d - and l -2-Hydroxyglutarate Inhibit the AlkB Family DNA Repair Enzymes under Physiological Conditions
    Fangyi Chen, Ke Bian, Qi Tang, Bogdan I. Fedeles, Vipender Singh, Zachary T. Humulock, John M. Essigmann, Deyu Li · 2017 · Chemical Research in Toxicology
85. A comparative study of short‐ and long‐TE 1H MRS at 3 T for in vivo detection of 2‐hydroxyglutarate in brain tumors
    Changho Choi, Sandeep Ganji, Keith Hulsey, Akshay Madan, Zoltán Z. Kovács, Ivan E. Dimitrov, Song Zhang, Kumar Pichumani, Dianne B. Mendelsohn, Bruce Mickey et al. · 2013 · NMR in Biomedicine
86. Detection of “oncometabolite” 2-hydroxyglutarate by magnetic resonance analysis as a biomarker of IDH1/2 mutations in glioma
    Juliya Kalinina, Anne Carroll, Liya Wang, Qiqi Yu, Danny E. Mancheno, Shaoxiong Wu, Frank Liu, Jun Young Ahn, Miao He, Hui Z. Mao et al. · 2012 · Journal of Molecular Medicine
87. Melanoma epigenetics: novel mechanisms, markers, and medicines
    Jonathan J. Lee, Gëorge F. Murphy, Christine Guo Lian · 2014 · Laboratory Investigation
88. Presence of an oligodendroglioma-like component in newly diagnosed glioblastoma identifies a pathogenetically heterogeneous subgroup and lacks prognostic value: central pathology review of the EORTC_26981/NCIC_CE.3 trial
    Monika E. Hegi, Robert-Charles Janzer, Wanyu L. Lambiv, Thierry Gorlia, Mathilde C.M. Kouwenhoven, Christian Johannes Hartmann, Andreas von Deimling, Danielle Martinet, Nathalie Besuchet Schmutz, Annie‐Claire Diserens et al. · 2012 · Acta Neuropathologica
89. Analysis of TET Expression/Activity and 5mC Oxidation during Normal and Malignant Germ Cell Development
    Daniel Nettersheim, Lukas Carl Heukamp, Florian Fronhoffs, Marc J Grewe, Natalie Haas, Anke Waha, Friedemann U. Honecker, Andreas Waha, Glen Kristiansen, Hubert Schorle · 2013 · PLoS ONE
90. Oncogenic R132 IDH1 Mutations Limit NADPH for De Novo Lipogenesis through (D)2-Hydroxyglutarate Production in Fibrosarcoma Cells
    Mehmet G. Badur, Thangaselvam Muthusamy, Seth J. Parker, Shenghong Ma, Samuel K. McBrayer, Thekla Cordes, Jose H. Magaña, Kun‐Liang Guan, Christian M. Metallo · 2018 · Cell Reports
91. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
    Dusten J. Unruh, Makda Getachew Zewde, Adam Buss, Michael R. Drumm, Anh Nhat Tran, Denise M. Scholtens, Craig Horbinski · 2019 · Scientific Reports
92. Infratentorial IDH-mutant astrocytoma is a distinct subtype
    Rouzbeh Banan, Damian Stichel, Anja C. Bleck, Bujung Hong, Ulrich Lehmann, Abigail Kora Suwala, Annekathrin Reinhardt, Daniel Schrimpf, Rolf Buslei, Christine Stadelmann et al. · 2020 · Acta Neuropathologica
93. Molecular Pathways in Gliomagenesis and Their Relevance to Neuropathologic Diagnosis
    Christina Appin, Daniel Jay Brat · 2014 · Advances in Anatomic Pathology
94. Genomic Landscape of Somatic Alterations in Esophageal Squamous Cell Carcinoma and Gastric Cancer
    Nan Hu, Mitsutaka Kadota, Huaitian Liu, Christian C. Abnet, Hua Su, Hailong Wu, Neal D. Freedman, Howard Hua Yang, Chaoyu Wang, Chunhua Yan et al. · 2016 · Cancer Research
95. IDH1/2 Mutations Predict Shorter Survival in Chondrosarcoma
    Iwona A. Lugowska, Paweł Teterycz, Michał Mikuła, Maria Kulecka, Anna Kluska, Aneta Bałabas, Magdalena Piątkowska, Michał Wągrodzki, Andrzej Pieńkowski, Piotr Lukasz Rutkowski et al. · 2018 · Journal of Cancer
96. Nanotechnology for treatment of glioblastoma multiforme
    Justin S. Michael, Bong‐Seop Lee, Miqin Zhang, John S. Yu · 2018 · Journal of Translational Internal Medicine
97. Chondrosarcoma-from Molecular Pathology to Novel Therapies
    Agnieszka E. Zając, Sylwia Kopeć, Bartłomiej Szostakowski, Mateusz Jacek Spalek, Michał Fiedorowicz, Elżbieta Bylina, Paulina Filipowicz, Anna Szumera‐Ciećkiewicz, Andrzej Tysarowski, Anna Malgorzata Czarnecka et al. · 2021 · Cancers
98. Molecular Pathology of Gliomas
    Kristyn Galbraith, Matija Snuderl · 2021 · Surgical pathology clinics
99. Pyroptosis, ferroptosis, and autophagy cross-talk in glioblastoma opens up new avenues for glioblastoma treatment
    Sicheng Wan, Guanghui Zhang, Ruochen Liu, Muhammad Nadeem Abbas, Hongjuan Cui · 2023 · Cell Communication and Signaling
100. IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution
     Chien‐Chin Lin, Hsin‐An Hou, Wen‐Chien Chou, Yuan‐Yeh Kuo, Chieh‐Yu Liu, Chien‐Yuan Chen, Yan-Jun Lai, Mei‐Hsuan Tseng, Chi‐Fei Huang, Ying‐Chieh Chiang et al. · 2013 · American Journal of Hematology